에서 실시간으로 운영 중이에요! 자세히 알아보기
PCRX 아이콘

Pacira BioSciences
PCRX

36.34 USD
+0.01
0.03%
장 마감 시점 업데이트됨 10월 16일 PM 4:00 EDT
1일
0.03%
5일
0%
1개월
45.89%
3개월
41.95%
6개월
52.31%
연초 이후
48.57%
1년
59.6%
5년
-31.54%
10년
7.99%
 

소개: Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.

직원 수: 829

건강관리 의약품 제조업체 - 전문의약품 및 제네릭

뉴스

긍정적
중립
부정적
투자 심리 3개월
긍정적 28.6%
중립 60.7%
부정적 10.7%
부정적
Benzinga
14시간 전
Top 3 Health Care Stocks That May Fall Off A Cliff In October
As of Oct. 16, 2026, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Top 3 Health Care Stocks That May Fall Off A Cliff In October
중립
Business Wire
4일 전
Pacira BioSciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Pacira BioSciences, Inc. - PCRX
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Pacira BioSciences, Inc. (NasdaqGS: PCRX) to Viatris Inc. (NasdaqGS: VTRS). Under the terms of the proposed transaction, shareholders of Pacira will receive $36.50 in cash for each share of Pacira that they own. KSF is seeking to determine whether this consideration and the process that led to it ar.
Pacira BioSciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Pacira BioSciences, Inc. - PCRX
중립
PRNewsWire
5일 전
SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Pacira BioSciences, Inc. (NASDAQ: PCRX)
NEW YORK, Oct. 11, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC  (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Pacira BioSciences, Inc. (NASDAQ: PCRX ) related to its sale to Viatris Inc. Under the terms of the proposed transaction, Pacira shareholders are expected to receive $36.50 in cash per share.
SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Pacira BioSciences, Inc. (NASDAQ: PCRX)
중립
Zacks Investment Research
7일 전
Viatris to Buy Pacira for $1.65B to Expand Non-Opioid Pain Portfolio
VTRS is set to acquire PCRX for $1.65 billion in cash, adding two marketed pain therapies and a clinical-stage gene therapy candidate to expand its non-opioid pain portfolio.
Viatris to Buy Pacira for $1.65B to Expand Non-Opioid Pain Portfolio
중립
Newsfile Corp
8일 전
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Pacira BioSciences, Inc. (PCRX)
Bala Cynwyd, Pennsylvania--(Newsfile Corp. - October 8, 2026) - Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of Pacira BioSciences, Inc. ("Pacira BioSciences" or the "Company") (NASDAQ: PCRX) for possible breaches of fiduciary duty and other violations of federal and state law in connection with the sale of the Company to Viatris Inc. (NASDAQ: VTRS) for $36.50 per share in cash, representing an aggregate equity value of $1.65 billion. The investigation concerns whether the Pacira BioSciences Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the proposed transaction is paying fair value to shareholders of the Company.
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Pacira BioSciences, Inc. (PCRX)
중립
PRNewsWire
8일 전
PCRX SHAREHOLDER ALERT: ADEMI LLP INVESTIGATES WHETHER BUYOUT FAIRLY VALUES PACIRA BIOSCIENCES, INC.
PCRX shareholders will receive just $36.50 per share in cash, representing an aggregate equity value of $1.65 billion; Ademi LLP is investigating the deal price, benefits to company insiders, and restrictions on competing offers CLICK HERE TO JOIN MILWAUKEE, Oct. 8, 2026 /PRNewswire/ -- Ademi LLP is investigating whether the proposed acquisition of Pacira (NASDAQ: PCRX) by Viatris, provides fair value to Pacira's public shareholders and whether Pacira's Board adequately protected shareholder interests in negotiating and approving the transaction. Are You a PCRX Shareholder?
PCRX SHAREHOLDER ALERT: ADEMI LLP INVESTIGATES WHETHER BUYOUT FAIRLY VALUES PACIRA BIOSCIENCES, INC.
부정적
Schaeffers Research
8일 전
2 Stocks Drawing Bearish Options Activity Today
Options traders are taking a bearish stance on two stocks attracting unusual volume today: Pacira BioSciences Inc (NASDAQ:PCRX) and Ring Energy Inc (NYSEAMERICAN:REI).
2 Stocks Drawing Bearish Options Activity Today
긍정적
Investors Business Daily
8일 전
Pacira Biosciences Snags $1.65 Billion Viatris Takeover Deal; Shares Fly
Viatris pledged Thursday to buy small biotech company Pacira Biosciences for $1.65 billion, sending Pacira stock skyrocketing.
Pacira Biosciences Snags $1.65 Billion Viatris Takeover Deal; Shares Fly
긍정적
The Motley Fool
8일 전
Why Pacira BioSciences Skyrocketed Today
Pacira BioSciences is being bought out by Viatrias. The deal values the company at $36.50 per share or about $1.65 billion.
Why Pacira BioSciences Skyrocketed Today
긍정적
WSJ
8일 전
Viatris to Buy Pacira BioSciences for $1.65 Billion
Viatris has agreed to buy pain-drug maker Pacira BioSciences for $1.65 billion in a deal that expands the healthcare company's medicines portfolio.
Viatris to Buy Pacira BioSciences for $1.65 Billion
뉴스 순위 보기
Lightweight Charts™를 사용해 가격 차트를 구현했어요.